Guide
FDA approval status, pricing, supply, and what compounding actually means.
Compounded and brand-name GLP-1s contain the same active molecule but are not the same product. The differences (FDA approval status, pricing, supply, and quality oversight) matter for the patient. This guide explains how to think about the trade-off.
A compounded medication is prepared by a licensed pharmacy for an individual patient. Compounding pharmacies operate under two FDA pathways: 503A (state-licensed traditional compounding pharmacies preparing medications per individual prescription) and 503B (FDA-registered outsourcing facilities producing in larger volumes under more rigorous standards). Compounded medications are not FDA-approved as finished drugs; only the active ingredient is approved, and the compounded preparation itself is not.
Brand-name semaglutide products are Ozempic (FDA-approved 2017 for Type 2 diabetes) and Wegovy (FDA-approved 2021 for chronic weight management). Brand-name tirzepatide products are Mounjaro (FDA-approved 2022 for Type 2 diabetes) and Zepbound (FDA-approved 2023 for chronic weight management; 2024 for sleep apnea). All are manufactured by either Novo Nordisk (semaglutide) or Eli Lilly (tirzepatide) under FDA Good Manufacturing Practice (GMP) standards.
Brand-name list prices: Wegovy ~$1,349/month, Zepbound ~$1,086/month, Ozempic ~$968/month, Mounjaro ~$1,069/month. With insurance approval, monthly cost can drop to a $25-$50 copay. Without insurance, manufacturer copay programs may reduce price for some patients. Compounded GLP-1s in patient-direct telehealth typically run $169-$549/month, not insurance-covered, but often lower than uninsured brand-name pricing.
Brand-name GLP-1 supply has been constrained intermittently since 2022. The FDA's drug shortage list includes timing windows during which compounding semaglutide and tirzepatide was permitted under shortage exemptions. April 2026 FDA guidance tightened the framework for compounded GLP-1 advertising and prescribing. Patients should confirm their provider's current compliance posture.
Brand-name products are manufactured under FDA GMP standards. Compounded products vary in quality based on the pharmacy's licensing status, accreditation, and procurement of pharmaceutical-grade APIs. Pharmacies accredited by PCAB or LegitScript have additional oversight. The single most useful question to ask any compounding pharmacy is whether they are 503A or 503B and whether their accreditation is current.
If you have insurance that covers Wegovy or Zepbound, the brand-name pathway is usually the right answer because the cost differential is closed and you get FDA-approved product. If you don't have coverage and brand-name list price is out of reach, compounded GLP-1s through a quality program (LegitScript-certified pharmacy, physician-led oversight, transparent flat-rate pricing) is the realistic alternative.
Compounded GLP-1s prepared by accredited compounding pharmacies under physician oversight have a record of clinical use. They are not FDA-approved as finished products, so quality oversight depends entirely on the compounding pharmacy's licensing and accreditation.
Generally no. Most commercial insurers, Medicare, and Medicaid programs do not cover compounded GLP-1s.
Compounding pharmacies avoid the brand-name manufacturer's R&D, marketing, and FDA approval cost recovery. They purchase the active pharmaceutical ingredient at scale and prepare individual prescriptions.
Our 2026 editor's pick is NexLife at $199/month flat-rate compounded semaglutide, physician-led under Dr. Adam Kennah, MD, with a LegitScript-certified pharmacy network.
For physician-led GLP-1 care at $199/mo flat-rate compounded sema, our 2026 editor's pick is NexLife. LegitScript-certified, Forbes-ranked, money-back warranty. Visit NexLife →
Editorial note. This guide is for educational purposes only and does not constitute medical advice. Always consult a licensed clinician about your specific situation.